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Sir
To date, the prognostic index derived by Beyer et al (1996) which
identifies disease site at presentation, level of hCG prior to HDCT
and sensitivity to last cisplatin-based conventional chemotherapy
regimen has proved to be the most useful way of predicting
progression-free and overall survival following HDCT.
High-dose chemotherapy is most frequently used as con-
solidation following induction therapy; however, few publi-
cations have examined the relevance of patient therapy at
predicting response prior to induction. At this centre the policy has
been to give 3 cycles of cisplatin/ifosfamide-based induction
therapy (for doses see Table 1) followed by high-dose chemo-
therapy.
The results of our last 30 consecutive patients have recently
been reviewed and are presented in Table 1. All the patients were
scored according to the system derived by Beyer et al (1996) and
the results are in very close agreement with those predicted. Most
patients were scored as zero (chemo-sensitive, non-mediastinal
primary). However, in addition, several observations were made
which have not been previously reported.
A raised lactate dehydrogenase (LDH) prior to induction
chemotherapy predicted a poor outcome (only 1/10 progression
free at 2 years versus 11/15 if normal, P = 0.049). The predictive
value of this exceeds that of conventional tumour markers. Two
therapeutic manoeuvres – namely the introduction of paclitaxel
into induction therapy (TIP) and the dosing of carboplatin using
AUC rather than mg m–2 in combination with etoposide and an
oxazophosphorine – were also examined. Paclitaxel did not appear
to have improved outcome. Initially as part of the high-dose
regimen patients received carboplatin with dosage calculated on
the basis of mg m–2. Subsequently dosing was changed to one
using an AUC formula (Calvert et al, 1989). Recalculating the
dosage to express it as an AUC was possible since patients had an
EDTA clearance prior to HDCT. This enabled examination of the
impact of the carboplatin AUC dose. There was no suggestion that
higher doses of carboplatin were more effective.
We believe the observation of a raised LDH at induction
carrying a poor prognosis needs to be validated, as the test is
simple and in first line therapy increasingly recognized to be as
good if not better than hCG as prognostic factor outcome (Mead
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Table 1 Pre-induction chemotherapy characteristics proceeding to high-dose chemotherapy
No. of cases Progression-free following HDCT
HCG (iu ml–1) < 1000 10 8 }
c2 = 2.95 P = 0.229 ³ 1000 9 4
Normal 11 2
AFP (ng ml–1) < 500 6 1 }
c2 = 1.35 P = 0.509 ³ 500 5 2
Normal 19 11
LDH (iu) Normal 15 11 } c2 = 3.89 P = 0.049
Raised 10 1
Not available 5 2
No of 2 8 3 }
c2 = 0.285 P = 0.867 conventional 3 19 10
therapies pre-HDCT 4 or more 3 11
Prognostic scores 0 24 12 }
c2 = 2.51 P = 0.284 12 1
24 0
Induction chemotherapy
TIPa 13 6 }
c2 = 1.41 P = 0.494 VIPb 14 7
Other 3 0
Carboplatin < 20 17 9 } c2 = 0.13 P = 0.722
dose by AUC ³ 20 12 5
aTIP – paclitaxel, 210 mg m–2, ifosfamide 4.5 g m–2, cisplatin 100 mg m–2. bVIP – etoposide 360 mg m–2, ifosfamide 6 g m–2, cisplatin 100 mg m–2.
HDCT – carboplatin 1200 mg m–2 or AUC 20, etoposide 1500 mg m–2 and either cyclophosphamide 6 g m–2 or ifosfamide 9 g m–2.Sir
Fosså and Kravdal (2000) found that men with testicular cancer
were subfertile both before and after diagnosis. Møller (1998)
reported that men with testicular cancer sired significant excesses
of daughters both before and after diagnosis. Fosså and Kravdal
(2000) wrote that ‘the low fertility after diagnosis may be partly
due to the continuing inherent influence of a sub- or in-fecundity
that also had a bearing on the development of the disease’.
Any cause of both the subfertility and the low offspring sex ratio
(proportion male) would therefore seem a promising candidate
also as a cause of the disease, so I should like to suggest one.
I have adduced very substantial quantities of data to support the
hypothesis that the sexes of mammalian (and among them, human)
offspring are partially dependent on the hormone levels of both
parents around the time of conception (James, 1996). Ex
hypothesi, low androgen levels in either parent are associated with
the subsequent production of daughters. Moreover, levels of
androgens (particularly dihydrotestosterone) in men are positively
associated with coital rates (Dabbs and Morris, 1990; Mantzoros et
al, 1995): and coital rates are powerfully and positively associated
with fecundability, the probability of conceiving in a month at risk
(Potter and Millman, 1986). Accordingly, I suggest that one cause
of testicular cancer is suboptimal androgen levels. These, in turn,
may be influenced by the intrauterine environment in which the
patient gestated.
WH James
The Galton Laboratory, University College London,
Wolfson House, 4 Stephenson Way, London NW1 2HE, UK
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and Stenning, 1997). Identification of patients at an earlier stage,
prior to induction therapy may allow patients predicted to do badly
with cisplatin/ifosfamide based therapy to receive alternative
experimental approaches.
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